SciSparc (NASDAQ:SPRC) Shares Down 3.4% – Here’s Why

SciSparc Ltd. (NASDAQ:SPRC)’s share price fell 3.4% on Tuesday. The stock traded as low as $3.89 and last traded at $3.94. Approximately 22,054 shares traded hands during trading, an increase of 12% from the average session volume of 19,719 shares. The stock had previously closed at $4.08.

Trending Headlines about SciSparc

Here are the key news stories impacting SciSparc this week:

• Positive Sentiment: SciSparc announced that it will evaluate Agentic AI technologies, companies and business opportunities, potentially giving the clinical-stage pharmaceutical company a new growth narrative in high-interest cybersecurity and financial-technology markets. SciSparc Announces Transformation into Agentic AI-Powered Technologies
• Positive Sentiment: Investor interest was also supported by an earlier NeuroThera and CliniQuantum update describing GPU-accelerated analysis of more than 7.3 billion three-gene combinations. The company said the process was substantially faster than a CPU-only approach, though the work was only a computational benchmark and did not demonstrate clinical validity or near-term commercial value. SciSparc Jumps as Investors React to NeuroThera’s Quantum-Analysis Update
• Neutral Sentiment: Trading was repeatedly paused under the Limit Up-Limit Down, or LULD, mechanism. These pauses indicate unusually rapid price movements and help explain the stock’s extreme intraday volatility, but they are not themselves a change in the company’s fundamentals.
• Negative Sentiment: SciSparc cautioned that its Agentic AI strategy may not lead to a transaction, commercial agreement or revenue-generating activity. The pivot may also raise questions about the company’s existing pharmaceutical strategy and execution risk.
• Negative Sentiment: Fundamentals remain weak: recent reporting showed limited revenue, a substantial net loss and insufficient cash to fund operations for at least the next year, creating substantial doubt about the company’s ability to continue as a going concern. One reported insider transaction in the past six months was a sale, not a purchase.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a research note on Friday, August 21st. Wall Street Zen upgraded SciSparc to a “hold” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

SciSparc Stock Down 44.9%

The stock has a fifty day moving average of $5.46 and a 200-day moving average of $5.83.

SciSparc (NASDAQ:SPRC) last released its earnings results on Friday, August 14th. The company reported ($4.85) earnings per share for the quarter. The firm had revenue of $0.14 million for the quarter.

About SciSparc

SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based specialty pharmaceutical company focused on developing therapies for disorders of the central nervous system. The company’s research is centered on cannabinoid-based pharmaceutical compositions and combinations intended to address conditions with limited treatment options.

SciSparc’s development pipeline has included SCI-110, an investigational cannabinoid-based treatment being studied for Tourette syndrome and obstructive sleep apnea, as well as SCI-210, a combination therapy under development for autism spectrum disorder.